Financial Contrast: Adaptimmune Therapeutics (ADAP) and The Competition

Adaptimmune Therapeutics (NASDAQ: ADAP) is one of 286 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its rivals? We will compare Adaptimmune Therapeutics to similar companies based on the strength of its risk, analyst recommendations, dividends, earnings, valuation, profitability and institutional ownership.

Analyst Ratings

This is a summary of recent ratings for Adaptimmune Therapeutics and its rivals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Adaptimmune Therapeutics 0 1 3 0 2.75
Adaptimmune Therapeutics Competitors 893 3287 11783 235 2.70

Adaptimmune Therapeutics presently has a consensus target price of $12.50, indicating a potential upside of 87.13%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 43.26%. Given Adaptimmune Therapeutics’ stronger consensus rating and higher possible upside, research analysts clearly believe Adaptimmune Therapeutics is more favorable than its rivals.

Volatility & Risk

Adaptimmune Therapeutics has a beta of 1.35, suggesting that its share price is 35% more volatile than the S&P 500. Comparatively, Adaptimmune Therapeutics’ rivals have a beta of 5.97, suggesting that their average share price is 497% more volatile than the S&P 500.

Valuation & Earnings

This table compares Adaptimmune Therapeutics and its rivals top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Adaptimmune Therapeutics $14.20 million -$71.57 million -8.79
Adaptimmune Therapeutics Competitors $284.49 million $34.10 million 64.53

Adaptimmune Therapeutics’ rivals have higher revenue and earnings than Adaptimmune Therapeutics. Adaptimmune Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Insider & Institutional Ownership

54.2% of Adaptimmune Therapeutics shares are held by institutional investors. Comparatively, 49.7% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 24.5% of Adaptimmune Therapeutics shares are held by company insiders. Comparatively, 17.5% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.


This table compares Adaptimmune Therapeutics and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Adaptimmune Therapeutics -138.46% -27.99% -21.47%
Adaptimmune Therapeutics Competitors -5,229.27% -213.46% -38.10%


Adaptimmune Therapeutics beats its rivals on 8 of the 13 factors compared.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients. The Company engineers TCRs to increase the affinity to cancer specific peptides in order to destroy cancer cells in patients. The Company is developing multiple SPEAR T-cells to different target peptides in selected disease indications to increase the probability of treating patients with a given disease indication and potentially the ability for re-treatment of patients with a different SPEAR T-cell. It has three SPEAR T-cells in clinical trials, which are directed to cancer testis antigens, NY-ESO-1, MAGE-A4 and MAGE-A10.

Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply